0HKD Stock Overview
Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AxoGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.30 |
| 52 Week High | US$10.82 |
| 52 Week Low | US$3.50 |
| Beta | 1.06 |
| 11 Month Change | 7.26% |
| 3 Month Change | -7.83% |
| 1 Year Change | n/a |
| 33 Year Change | -66.79% |
| 5 Year Change | n/a |
| Change since IPO | -74.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HKD | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 7.2% | -1.7% | -0.9% |
| 1Y | n/a | -13.2% | 6.3% |
Return vs Industry: Insufficient data to determine how 0HKD performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how 0HKD performed against the UK Market.
Price Volatility
| 0HKD volatility | |
|---|---|
| 0HKD Average Weekly Movement | 9.2% |
| Medical Equipment Industry Average Movement | 5.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HKD has not had significant price volatility in the past 3 months.
Volatility Over Time: 0HKD's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 427 | Karen Zaderej | www.axogeninc.com |
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
AxoGen, Inc. Fundamentals Summary
| 0HKD fundamental statistics | |
|---|---|
| Market cap | US$316.42m |
| Earnings (TTM) | -US$21.28m |
| Revenue (TTM) | US$163.73m |
1.9x
P/S Ratio-14.9x
P/E RatioIs 0HKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HKD income statement (TTM) | |
|---|---|
| Revenue | US$163.73m |
| Cost of Revenue | US$31.72m |
| Gross Profit | US$132.00m |
| Other Expenses | US$153.28m |
| Earnings | -US$21.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 80.62% |
| Net Profit Margin | -13.00% |
| Debt/Equity Ratio | 53.4% |
How did 0HKD perform over the long term?
See historical performance and comparison